People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2019 |
Carole E. Nuechterlein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carole E. Nuechterlein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Booth | 1 | 12 |
| Clay Thorp | 1 | 10 |
| Daniel Geffken | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| Steven E. Hall | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Peter Wirth | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Henri Termeer | 1 | 3 |
| Bruce L Booth | 1 | 2 |
| Carole Nuechterlein | 1 | 2 |
| Steven Hall | 1 | 2 |
| Clay E. Thorp | 1 | 1 |
| Dimitri Krainc | 1 | 1 |
| Cornelis Been | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.